New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - rivaroxaban 10mg - film coated tablet - 10 mg - active: rivaroxaban 10mg excipient: croscarmellose sodium hypromellose   iron oxide red lactose monohydrate macrogol 3350 magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - rivaroxaban 15mg - film coated tablet - 15 mg - active: rivaroxaban 15mg excipient: croscarmellose sodium hypromellose   iron oxide red lactose monohydrate macrogol 3350 magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age >= 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - rivaroxaban 20mg - film coated tablet - 20 mg - active: rivaroxaban 20mg excipient: croscarmellose sodium hypromellose   iron oxide red lactose monohydrate macrogol 3350 magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age >= 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tranexamic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: macrogol 8000; vanillin; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; purified talc; povidone; basic butylated methacrylate copolymer - oral administration hereditary angioneurotic oedema. short term use in the treatment of hyphaema and in patients with established coagulopathies who are undergoing minor surgery. menorrhagia.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - rivaroxaban 2.5mg - film coated tablet - 2.5 mg - active: rivaroxaban 2.5mg excipient: croscarmellose sodium hypromellose   iron oxide yellow lactose monohydrate macrogol 3350 magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide - in combination with aspirin, is indicated for the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad).

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - rivaroxaban 10mg;   - film coated tablet - 10 mg - active: rivaroxaban 10mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 04f530012 sodium laurilsulfate - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - rivaroxaban 15mg;   - film coated tablet - 15 mg - active: rivaroxaban 15mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 04f530006 sodium laurilsulfate - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - rivaroxaban 20mg;   - film coated tablet - 20 mg - active: rivaroxaban 20mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 04f530010 sodium laurilsulfate - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.

United States - English - NLM (National Library of Medicine)

indoco remedies limited - apixaban (unii: 3z9y7uwc1j) (apixaban - unii:3z9y7uwc1j) - apixaban tablets are indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. apixaban tablets are indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe), in patients who have undergone hip or knee replacement surgery. apixaban tablets are indicated for the treatment of dvt. apixaban tablets are indicated for the treatment of pe. apixaban tablets are indicated to reduce the risk of recurrent dvt and pe following initial therapy. apixaban tablets are contraindicated in patients with the following conditions: • active pathological bleeding [see warnings and precautions (5.2) and adverse  reactions(6.1)] • severe  hypersensitivity  reaction  to  apixaban (e.g.,  anaphylactic  reactions)  [see  adverse reactions (6.1)] risk summary the limited available data on apixaban tablets  use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental

Uganda - English - National Drug Authority

south egypt drug industries co. (sedico) - amoxicillintrihydrate + potassium clavulanate - oral solid ordinary film-coated tablets - 875 mg + 125 mg